Clinical Trial Update: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection [Phase 2]

View source ↗

Summary

A Phase 2 study of Rilematovir (JNJ-53718678) in adult outpatients with respiratory syncytial virus infection was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Rilematovir (rilematovir)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Respiratory Syncytial Virus | Phase 2 | Status: TERMINATED | Results posted: 2023-04-21